EUCTR2016-000240-34-PL进行中（未招募）1 期
The Efficacy and Safety of Intra-Arterial Administration of REX-001 to Treat Ischaemic Rest Pain in Subjects with Critical Limb Ischaemia Rutherford Category 4 and Diabetes Mellitus: A Pivotal, Placebo-Controlled, Double-Blind, Parallel-Group, Adaptive Trial - Salamander
Rexgenero Limited0 个研究点目标入组 60 人开始时间: 2017年4月3日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •To be eligible for this trial subjects must satisfy all of the following criteria:
- •1. Aged = 18 to = 85 years.
- •2. Diagnosis of Type I or II DM, established more than one year ago.
- •3. Subjects with poor or no (surgical or endovascular) revascularization option classified as CLI Rutherford Category 4.
- •The blood circulation in these subjects must be compromised at screening defined as:
- •Ankle systolic pressure < 50 mm Hg, or
- •Toe systolic pressure < 30 mm Hg, or
- •TcpO2 < 30 mm Hg, and
- •Flat or barely pulsatile ankle or metatarsal PVR
- •The subject should have rest pain without tissue loss, and the rest pain must be persistent and require analgesics for at least two weeks for the subject to be eligibile. Subjects with non-compressible or calcified vessels must qualify on toe pressure or tcpO2.
- •Poor or no revascularization option means that, in the opinion of the Investigator, revascularization using surgical or endovascular methods are not feasible due to poor anatomy of existing vessels and/or existing comorbidity and/or previously failed surgical or endovascular revascularization.
- •4. In the opinion of the Investigator, the subject is controlled on medical therapy indicated for CLI (unless there is a documented contraindication or intolerance) and pain management is optimized.
- •5. Women of childbearing potential must have a negative pregnancy test at screening. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. Men and women who are sexually active shall use effective contraceptive methods for the duration of their participation in this study if the partner of the male participant, or if the female participant is of childbearing potential. Effective contraceptive methods are e.g.:
- •Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal),
- •Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable),
- •Intrauterine device (IUD),
- •Intrauterine hormone-releasing system (IUS),
- •Bilateral tubal occlusion,
- •Vasectomised partner, or
- •Sexual abstinence.
- •The use of this contraceptive method should be continued for at least the duration of participation in the study, and should be continued thereafter as long as indicated by the study doctor.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 32
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 28
排除标准
- •Subjects meeting any of the following criteria must not be enrolled in the trial:
- •1. Advanced CLI defined as presence of major tissue loss (i.e. significant ulceration and/or gangrene) proximal to the metatarsal heads (CLI Rutherford Category 6). Significant ulceration/gangrene means any ulceration that extends beyond the subcutaneous tissue layer, or any gangrene or tissue necrosis proximal to the metatarsal heads.
- •2. CLI Rutherford Category 5.
- •3. Uncontrolled or untreated proliferative retinopathy.
- •4. Failed surgical or endovascular revascularization on the index leg within 10 days prior to screening.
- •5. Subjects in whom arterial insufficiency in the lower extremity is the result of acute limb ischemia or an immunological or inflammatory or non-atherosclerotic disorder (e.g., thromboangiitis obliterans (Buerger’s Disease), or systemic sclerosis (both limited and diffuse forms).
- •6. Clinical evidence of invasive infection on index leg defined as major tissue loss at the mid-foot or heel involving tendon and/or bone, and/or when intravenous antibiotics are required to treat the infection according to the Investigator.
- •7. At screening, the presence of only neuropathic ulcers on the index leg.
- •8. Amputation at or above the talus on the index leg.
- •9. Planned major amputation within the first month after randomization.
- •10. On the index leg, use of concomitant wound treatments not currently approved for ischemic wound-healing within 30 days prior to screening or plans to initiate new, nonstandard-of-care treatments to the index leg during the trial.
- •11. Blood clotting disorder not caused by medication (e.g., thrombophilia).
- •12. Severe hypertension according to the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. (34)
- •13. A platelet count < 50,000/µL.
- •14. International normalized ratio (INR) > 1.5.
- •15. Evidence of moderate to severe hepatocellular dysfunction according to the treating physician.
- •16. Positive test for human immunodeficiency virus 1 (HIV 1), HIV 2, hepatitis B virus (HBV), hepatitis C virus (HCV) or Treponema pallidum.
- •17. Subjects who may not be healthy enough to successfully complete all protocol requirements including BM collection, or who are not expected to survive more than 12 months, or in whom results may be particularly difficult to assess, as assessed by the Investigator. For example:
- •a. Concurrent severe congestive heart failure (New York Heart Association Classes III and IV).
- •b. Life-threatening ventricular arrhythmias, unstable angina (characterized by increasingly frequent episodes with modest exertion or at rest, worsening severity, and prolonged duration), and/or myocardial infarction within four weeks before screening.
- •c. Coronary artery bypass grafting or percutaneous coronary intervention within one month before screening.
- •d. A renal and/or carotid revascularization procedure within one month of screening.
- •e. Transient ischemic attack within three months prior to screening.
- •f. Deep vein thrombosis within three months prior to screening.
- •g. Subjects with immunocompromised conditions, organ transplant recipients and/or subjects in need of immunosuppressive therapy.
- •h. Neurological dementia (i.e., Alzheimer’s Disease).
- •18. Subjects who participate in another clinical interventional trial.
- •19. Subjects who have been treated with experimental medication within 30 days of screening.
- •20. Subjects who participated in other cell thera
研究者
相似试验
进行中（未招募）
1 期
A clinical trial to test the efficacy and safety of a bone marrow cell preparation to treat Critical Limb Ischemia in Subjects with Diabetes Mellitus.EUCTR2016-000240-34-ATRexgenero Limited60
进行中（未招募）
1 期
A clinical trial to test the efficacy and safety of a bone marrow cell preparation to treat Critical Limb Ischemia in Subjects with Diabetes Mellitus.Critical Limb Ischemia in patients with Diabetes MellitusMedDRA version: 19.1Level: LLTClassification code 10077142Term: Limb ischemiaSystem Organ Class: 100000004866MedDRA version: 19.1Level: LLTClassification code 10058069Term: Critical limb ischemiaSystem Organ Class: 100000004866MedDRA version: 19.1Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2016-000240-34-NLRexgenero Limited60
进行中（未招募）
1 期
A clinical trial to test the efficacy and safety of intra-arterial administration of REX-001 to treat ischemic ulcers in subjects with critical limb ischaemia Rutherford Category 5 and diabetes mellitus.Critical Limb Ischemia in patients with Diabetes MellitusMedDRA version: 20.0Level: LLTClassification code 10077142Term: Limb ischemiaSystem Organ Class: 100000004866MedDRA version: 20.0Level: LLTClassification code 10058069Term: Critical limb ischemiaSystem Organ Class: 100000004866MedDRA version: 20.0Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2016-003980-21-DERexgenero Limited60
进行中（未招募）
1 期
A clinical trial to test the efficacy and safety of intra-arterial administration of REX-001 to treat ischaemic ulcers in subjects with Critical Limb Ischaemia Rutherford Category 5 and Diabetes Mellitus.Critical Limb Ischemia in patients with Diabetes MellitusMedDRA version: 21.1Level: LLTClassification code 10077142Term: Limb ischemiaSystem Organ Class: 100000004866MedDRA version: 24.0Level: LLTClassification code 10058069Term: Critical limb ischemiaSystem Organ Class: 100000004866MedDRA version: 20.0Level: PTClassification code 10012601Term: Diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2016-003980-21-PTRexgenero Limited78
进行中（未招募）
1 期
A clinical trial to test the efficacy and safety of a bone marrow cell preparation to treat Critical Limb Ischemia in Subjects with Diabetes Mellitus.Critical Limb Ischemia in patients with Diabetes MellitusMedDRA version: 21.1 Level: LLT Classification code 10077142 Term: Limb ischemia System Organ Class: 100000004866MedDRA version: 21.1 Level: LLT Classification code 10058069 Term: Critical limb ischemia System Organ Class: 100000004866MedDRA version: 20.0 Level: PT Classification code 10012601 Term: Diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2016-000240-34-PTRexgenero Limited60